These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24521156)
1. Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity. Loizidou EZ; Zeinalipour-Yazdi CD Chem Biol Drug Des; 2014 Jul; 84(1):99-107. PubMed ID: 24521156 [TBL] [Abstract][Full Text] [Related]
2. Modulation of proteasome subunit selectivity of syringolins. Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960 [TBL] [Abstract][Full Text] [Related]
3. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes. Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent and highly specific β Zhou T; Cai Y; Liang L; Yang L; Xu F; Niu Y; Wang C; Zhang JL; Xu P Bioorg Med Chem Lett; 2016 Dec; 26(23):5780-5784. PubMed ID: 27816516 [TBL] [Abstract][Full Text] [Related]
5. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors. Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746 [TBL] [Abstract][Full Text] [Related]
7. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790 [TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Activity of Isosyringolin A. Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978 [TBL] [Abstract][Full Text] [Related]
9. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i. Allardyce DJ; Bell CM; Loizidou EZ Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944 [TBL] [Abstract][Full Text] [Related]
10. Proteasome activity imaging and profiling characterizes bacterial effector syringolin A. Kolodziejek I; Misas-Villamil JC; Kaschani F; Clerc J; Gu C; Krahn D; Niessen S; Verdoes M; Willems LI; Overkleeft HS; Kaiser M; van der Hoorn RA Plant Physiol; 2011 Jan; 155(1):477-89. PubMed ID: 21045122 [TBL] [Abstract][Full Text] [Related]
11. Development of peptidomimetic boronates as proteasome inhibitors. Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651 [TBL] [Abstract][Full Text] [Related]
12. Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983 [TBL] [Abstract][Full Text] [Related]
13. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells. Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914 [TBL] [Abstract][Full Text] [Related]
14. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994 [TBL] [Abstract][Full Text] [Related]
16. Noncovalent inhibitors of human 20S and 26S proteasome based on trypsin inhibitor SFTI-1. Dębowski D; Cichorek M; Lubos M; Wójcik S; Łęgowska A; Rolka K Biopolymers; 2016 Sep; 106(5):685-96. PubMed ID: 27258473 [TBL] [Abstract][Full Text] [Related]
17. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits. Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763 [TBL] [Abstract][Full Text] [Related]
18. Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP. Hodošček M; Elghobashi-Meinhardt N Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30514002 [TBL] [Abstract][Full Text] [Related]
19. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214 [TBL] [Abstract][Full Text] [Related]